It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Explore criteria to identify altcoins safe for long-term holding, including fundamentals, liquidity, and community support. Start evaluating with confidence.
27,729 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Net migration into the United States swung negative last year, the first such reversal since the Great Depression, si...
Tesla enters a pivotal period as AI-driven software and energy products meet traditional EV growth. This article asse...
Trump visits China this week as tariffs linger and midterm politics shape strategy. Investors weigh whether china off...
A big investor just bought millions of Grindr shares after the stock plunged. This article breaks down why grindr sto...
Binance withdraws its MiCA filing in Greece, signaling a broader EU strategy as July 1 approaches. European users fac...
Tech shares rallied as semiconductors staged a comeback, lifting the Nasdaq Composite by 0.9%. This article explains ...
When a quarterly miss hits the wires, investors scramble to interpret the fallout. This deep dive explains why calume...
Oil moved toward $110 a barrel after Iran signaled a broader escalation. The move adds risk to already tense energy m...
American Express is scrapping its long-standing unit-by-unit bonus race. The company now ties executive pay to overal...
May brought a sharp drop in oil markets as prices tumbled nearly 20%. This article breaks down what caused the move, ...
When a tech insider sells a large stake, investors weigh a range of signals. This guide breaks down what the move cou...